MDxHealth (NASDAQ:MDXH) Announces Quarterly Earnings Results, Misses Estimates By $0.06 EPS

MDxHealth (NASDAQ:MDXH) issued its quarterly earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06), Zacks reports. The company had revenue of $24.29 million for the quarter, compared to analysts’ expectations of $22.62 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. MDxHealth updated its FY 2025 guidance to EPS.

MDxHealth Stock Up 6.7%

Shares of NASDAQ:MDXH opened at $1.90 on Friday. MDxHealth has a fifty-two week low of $1.35 and a fifty-two week high of $3.50. The firm’s 50 day moving average price is $1.60 and its 200 day moving average price is $1.85. The company has a quick ratio of 1.45, a current ratio of 1.54 and a debt-to-equity ratio of 3.14. The stock has a market cap of $89.85 million, a price-to-earnings ratio of -1.25 and a beta of 1.32.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.